Logo image of CRNX

CRINETICS PHARMACEUTICALS IN (CRNX) Stock Fundamental Analysis

NASDAQ:CRNX - Nasdaq - US22663K1079 - Common Stock - Currency: USD

33.76  +0.24 (+0.72%)

After market: 33.76 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CRNX. CRNX was compared to 567 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CRNX as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, CRNX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CRNX has reported negative net income.
In the past year CRNX has reported a negative cash flow from operations.
In the past 5 years CRNX always reported negative net income.
CRNX had a negative operating cash flow in each of the past 5 years.
CRNX Yearly Net Income VS EBIT VS OCF VS FCFCRNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

Looking at the Return On Assets, with a value of -20.80%, CRNX is in the better half of the industry, outperforming 78.48% of the companies in the same industry.
With an excellent Return On Equity value of -22.52%, CRNX belongs to the best of the industry, outperforming 85.01% of the companies in the same industry.
Industry RankSector Rank
ROA -20.8%
ROE -22.52%
ROIC N/A
ROA(3y)-33.7%
ROA(5y)-34.4%
ROE(3y)-38.05%
ROE(5y)-38.05%
ROIC(3y)N/A
ROIC(5y)N/A
CRNX Yearly ROA, ROE, ROICCRNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

CRNX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRNX Yearly Profit, Operating, Gross MarginsCRNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K -80K -100K

More info and screens

8

2. Health

2.1 Basic Checks

CRNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CRNX has more shares outstanding
The number of shares outstanding for CRNX has been increased compared to 5 years ago.
There is no outstanding debt for CRNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRNX Yearly Shares OutstandingCRNX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CRNX Yearly Total Debt VS Total AssetsCRNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

2.2 Solvency

An Altman-Z score of 16.67 indicates that CRNX is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 16.67, CRNX belongs to the best of the industry, outperforming 92.95% of the companies in the same industry.
There is no outstanding debt for CRNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 16.67
ROIC/WACCN/A
WACC10.04%
CRNX Yearly LT Debt VS Equity VS FCFCRNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

A Current Ratio of 23.04 indicates that CRNX has no problem at all paying its short term obligations.
CRNX has a better Current ratio (23.04) than 96.83% of its industry peers.
CRNX has a Quick Ratio of 23.04. This indicates that CRNX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 23.04, CRNX belongs to the best of the industry, outperforming 96.83% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 23.04
Quick Ratio 23.04
CRNX Yearly Current Assets VS Current LiabilitesCRNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

4

3. Growth

3.1 Past

CRNX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -0.27%.
The Revenue for CRNX has decreased by -74.15% in the past year. This is quite bad
The Revenue has been decreasing by -2.68% on average over the past years.
EPS 1Y (TTM)-0.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.22%
Revenue 1Y (TTM)-74.15%
Revenue growth 3Y-1.28%
Revenue growth 5Y-2.68%
Sales Q2Q%N/A

3.2 Future

CRNX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.40% yearly.
CRNX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 272.88% yearly.
EPS Next Y-12.59%
EPS Next 2Y-9.87%
EPS Next 3Y2.85%
EPS Next 5Y25.4%
Revenue Next Year182.26%
Revenue Next 2Y375.31%
Revenue Next 3Y386.03%
Revenue Next 5Y272.88%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CRNX Yearly Revenue VS EstimatesCRNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B 2.5B
CRNX Yearly EPS VS EstimatesCRNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CRNX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRNX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRNX Price Earnings VS Forward Price EarningsCRNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRNX Per share dataCRNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.87%
EPS Next 3Y2.85%

More info and screens

0

5. Dividend

5.1 Amount

CRNX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CRINETICS PHARMACEUTICALS IN

NASDAQ:CRNX (5/2/2025, 8:00:01 PM)

After market: 33.76 0 (0%)

33.76

+0.24 (+0.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-27 2025-02-27/amc
Earnings (Next)05-08 2025-05-08/amc
Inst Owners108.5%
Inst Owner Change-0.12%
Ins Owners1.91%
Ins Owner Change25.32%
Market Cap3.16B
Analysts85.22
Price Target77.37 (129.18%)
Short Float %10.72%
Short Ratio9.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.2%
Min EPS beat(2)-3.35%
Max EPS beat(2)2.94%
EPS beat(4)1
Avg EPS beat(4)-5.09%
Min EPS beat(4)-12.64%
Max EPS beat(4)2.94%
EPS beat(8)1
Avg EPS beat(8)-6%
EPS beat(12)2
Avg EPS beat(12)-6.51%
EPS beat(16)3
Avg EPS beat(16)-6.24%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)1
Avg Revenue beat(4)-19.44%
Min Revenue beat(4)-100%
Max Revenue beat(4)145.52%
Revenue beat(8)4
Avg Revenue beat(8)91.51%
Revenue beat(12)6
Avg Revenue beat(12)84.33%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.28%
PT rev (3m)0.57%
EPS NQ rev (1m)-1.46%
EPS NQ rev (3m)-0.48%
EPS NY rev (1m)-1.41%
EPS NY rev (3m)-5.25%
Revenue NQ rev (1m)-9.09%
Revenue NQ rev (3m)627.28%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.61%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3042.3
P/FCF N/A
P/OCF N/A
P/B 2.39
P/tB 2.39
EV/EBITDA N/A
EPS(TTM)-3.71
EYN/A
EPS(NY)-4.18
Fwd EYN/A
FCF(TTM)-2.45
FCFYN/A
OCF(TTM)-2.41
OCFYN/A
SpS0.01
BVpS14.15
TBVpS14.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -20.8%
ROE -22.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.7%
ROA(5y)-34.4%
ROE(3y)-38.05%
ROE(5y)-38.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 138.03%
Cap/Sales 369.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 23.04
Quick Ratio 23.04
Altman-Z 16.67
F-Score4
WACC10.04%
ROIC/WACCN/A
Cap/Depr(3y)244.79%
Cap/Depr(5y)160.44%
Cap/Sales(3y)173.94%
Cap/Sales(5y)166.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.22%
EPS Next Y-12.59%
EPS Next 2Y-9.87%
EPS Next 3Y2.85%
EPS Next 5Y25.4%
Revenue 1Y (TTM)-74.15%
Revenue growth 3Y-1.28%
Revenue growth 5Y-2.68%
Sales Q2Q%N/A
Revenue Next Year182.26%
Revenue Next 2Y375.31%
Revenue Next 3Y386.03%
Revenue Next 5Y272.88%
EBIT growth 1Y-52.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-20.4%
EBIT Next 3Y0.7%
EBIT Next 5YN/A
FCF growth 1Y-34.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-35.88%
OCF growth 3YN/A
OCF growth 5YN/A